|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.59 USD | +7.87% |
|
-1.29% | +7.49% |
| Apr. 19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
| Apr. 05 | Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication | MT |
2seventy bio, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 10.68 million compared to USD 56.18 million a year ago. Net loss was USD 56.82 million compared to USD 23.14 million a year ago.
Basic loss per share from continuing operations was USD 1.11 compared to USD 0.6 a year ago. Diluted loss per share from continuing operations was USD 1.11 compared to USD 0.6 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +7.49% | 219M | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
2SEVENTY BIO, INC. 
